PDCD1 and non-small cell lung carcinoma: In our meta-analysis, nineteen clinical trials with 931 patients were included to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small cell lung cancer.